Navigation Links
Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment

NEW YORK and NASSAU, The Bahamas, May 1 /PRNewswire-FirstCall/ -- Fincor (Pink Sheets: FINC) through a share split with Prospero Group (Pink Sheets: PRPG), a leading company in the field of water technologies, enlarges its portfolio with the new ACTRx Malaria and Dengue fever treatment. Fincor also acquired the WETTECH and Advanced Cavitation Technologies.

Fincor, acquired a majority of ACTRx International Inc., which combines several natural drugs to fight Malaria and Dengue fever and looks to become a premier global supplier of Malaria and Dengue cures, preventatives, maintenance and information products and services.

According to the World Health Organization, over 3 billion people live in areas at risk of malaria transmission, and annually over one million deaths are attributable to it -- 90% of which are to children under the age of five. However, malaria is a preventable and treatable disease, and the United Nations has called for elimination of all malaria deaths by the end of 2015, a goal which President Obama committed the United States to supporting on April 24th, 2009. The pharmaceutical package available through ACTRx will be a strong leader in the global fight against these unnecessary deaths from malaria. Additionally, it will assist in protecting and treating the 2.5 billion people at risk from dengue fever, and the 5 million dengue infections that occur each year. Prospero Group's intention is to research, review and objectively resolve the issues that keep these diseases active in our global society.

Fincor also acquired WETTECH marketed as Prospero Water Technologies and the Advanced Cavitation Technology.

About Fincor Inc.: Fincor Inc. is a technology and pharmaceutical company. It has recently acquired ACTRx International Inc. which produces Malaria and Dengue fever drugs in order to become the premier global supplier of Malaria and Dengue cures, preventatives, maintenance and information products and services. Fincor Inc. also acquired Advanced Cavitation Technology ("WETTECH"), which produces 1000 gallons (200 liters) per hour of high purity distilled water. Using this technology, consistently delivers the highest purity product water at the lowest overall cost with a minimum of maintenance.

Allowing the liquid to become the heat source, rather than a hot surface as in conventional applications eliminates the problems of scale build-up and fouling associated with the heating of impure liquids. So the device provides efficient, simple, inexpensive and reliable sources of distilled potable water for residential, commercial and industrial use. The Cavitation Technology operates at a very low operating cost and is the only water purification of its type to be fully clean-in-place (CIP) capable at such large capacity of delivering potable water.

SOURCE Fincor Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Web Portal Makes Organ Donation Easy
2. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
3. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
4. Argonne researcher studies what makes quantum dots blink
5. Modifying an anti-cancer drug makes it more specific
6. NanoLogix, Inc. Makes Stock Pick List
7. Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics
8. CSCs Dr. Robert M. Wah Makes Top 10 in 50 Most Powerful Physician Executives List
9. AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
10. University of Pennsylvania engineers reveal what makes diamonds slippery at the nanoscale
11. Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... and HOLLISTON, Mass. , ... Inc. (Nasdaq: HART ), a biotechnology company developing ... CEO Jim McGorry will present at the ... 1, 2015 at 2:30 p.m. PT. The presentation will ... for 30 days. Management will also be available at ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership ... Professionals (OPBAP) has been formalized with the signing of a Memorandum of Understanding. ... OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, ...
Breaking Biology Technology:
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
Breaking Biology News(10 mins):